Colossal Biosciences, a Texas-based startup, has raised $200 million in its Series C funding round, propelling the company to a valuation of over $10 billion. The funds will support its ambitious project to revive extinct species, including the woolly mammoth, thylacine, and dodo. Recent scientific breakthroughs have reportedly brought the company closer to their goal, with advancements such as mid-gestation marsupial embryo development in an artificial uterus. As the concept of de-extinction gains traction, there are growing discussions about whether the resurrection of these lost species is imminent, marking a significant moment in the field of biotechnology.